Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been given an average recommendation of “Hold” by the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is GBX 1,188.38 ($15.38).
A number of research analysts recently issued reports on HIK shares. Barclays reiterated an “underweight” rating on shares of Hikma Pharmaceuticals in a research report on Tuesday, July 10th. Peel Hunt reiterated a “hold” rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, August 1st. Jefferies Financial Group reiterated a “hold” rating and set a GBX 997 ($12.91) target price on shares of Hikma Pharmaceuticals in a research report on Friday, May 18th. Numis Securities downgraded shares of Hikma Pharmaceuticals to an “add” rating and boosted their target price for the company from GBX 1,300 ($16.83) to GBX 1,560 ($20.19) in a research report on Friday, May 18th. Finally, Citigroup reiterated a “buy” rating and set a GBX 1,675 ($21.68) target price on shares of Hikma Pharmaceuticals in a research report on Tuesday, July 3rd.
Shares of Hikma Pharmaceuticals stock traded up GBX 2.50 ($0.03) during trading on Tuesday, reaching GBX 1,673 ($21.66). 658,905 shares of the company traded hands, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 1-year low of GBX 814.20 ($10.54) and a 1-year high of GBX 2,346 ($30.37).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Article: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.